Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.
1. A method for treating antibiotic-induced obesity by restoring one or more bacterial species depleted in a gastrointestinal microbiota of a mammal following an antibiotic treatment, wherein said mammal has developed or is at risk of developing obesity as a result of the depletion of said bacterial species in the gastrointestinal microbiota of said mammal, said method comprising:
a) identifying one or more bacterial species which is statistically significantly diminished in a gastrointestinal microbiota sample obtained from the mammal following the antibiotic treatment as compared to a control gastrointestinal microbiota;
b) culturing bacteria from the one or more bacterial species determined in step (a) to be statistically significantly diminished in said sample as compared to the control; and
c) administering the cultured bacteria from step (b) to the mammal in an amount sufficient to increase the abundance of said bacteria in the gastrointestinal microbiota of said mammal and treat said antibiotic-induced obesity in said mammal.
2. The method of claim 1 , wherein step (a) involves screening of bacterial 16S rRNA gene(s) and/or bacterial gene(s) involved in metabolism.
3. The method of claim 1 , wherein step (a) involves PCR and/or high-throughput sequencing of bacterial 16S rRNA gene(s) and/or bacterial gene(s) involved in metabolism.
4. The method of claim 1 , wherein the cultured bacteria are administered to the mammal together with a buffering agent selected from the group consisting of sodium bicarbonate, milk, yoghurt, and infant formula.
5. The method of claim 1 , wherein the mammal is human.
6. The method of claim 1 , wherein the cultured bacteria are administered orally.
7. The method of claims 1 , wherein the mammal is a child.
8. The method of claim 1 , wherein the control is gastrointestinal microbiota from one or more non-obese age- and gender-matched healthy mammals of the same species that were not subject to the same antibiotic treatment.
9. The method of claim 1 , further comprising monitoring at least one parameter associated with obesity in said mammal.
10. The method of claim 1 , wherein the one or more bacterial species are from phylum Bacteroidetes.
11. The method of claim 1 , wherein the statistical significance is p<0.05 by Mann-Whitney U-test.
12. The method of claim 2 , wherein the functional gene(s) involved in metabolism is gene(s) encoding Butyryl CoA transferase (BCoAT).
13. The method of claim 1 , wherein step (a) comprises (i) determining the identity and amount(s) of one or more bacterial species present within said gastrointestinal microbiota sample, and (ii) comparing the amount(s) of the one or more bacterial species determined in step (a) to the amount(s) of the same bacterial species in the control.